Use of Proton Pump Inhibitors and risk of gastric cancer

References (1)

1. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer devel-opment after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28-35. [CrossRef] 2. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-5 3. [CrossRef]3. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium dif cile-associated diarrhea and proton pump inhibitor therapy: a me-ta-analysis. Am J Gastroenterol 2012; 107: 1001-10. [CrossRef] 4. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gas-tric acid-suppressive drugs. JAMA 2004; 292: 1955-60. [CrossRef] 5. Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Do-lor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a system-atic review. J Am Heart Assoc 2015; 4: e002245. [CrossRef] 6. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with re ux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22 [CrossRef] 7. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic re-view: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649-63. [CrossRef] 8. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure de nitions to control for protopathic bias. Pharmacoepide-miol Drug Saf 2007; 16: 250-8. [CrossRef]